STAT+: All eyes on data on Biogen’s tau therapy

STAT PlusNewsletterThe Readout All eyes on data on Biogen’s tau therapy The year of daraxonrasib, a wearable for a myeloma drug, and more biotech news from The Readout Manage alerts for this article Email this article Share this article By Meghana KeshavanJuly 13, 2026 Biotech Correspondent Meghana Keshavan[email protected]Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Lots happening in London these days, my colleague Andrew Joseph reports: At a pancreatic cancer meeting, researchers were buzzing about the implications of daraxonrasib, and at a major Alzheimer’s meeting, tau therapies are taking center stage.Advertisement Back here in the U.S., HHS has begun to craft national guidance on safely tapering SSRIs, and the FDA just cleared Sanofi’s wearable injector for a myeloma drug. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, Drug prices, research Submit a correction requestReprints Meghana Keshavan Biotech Correspondent Meghana Keshavan covers biotech and contributes to The Readout newsletter. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended Biotech July 13, 2026 STAT Plus: A breakthrough in pancreatic cancer has experts excited — and braced for what’s to come Biotech July 12, 2026 STAT Plus: Tau in the spotlight at Alzheimer’s conference Advertisement The Readout July 10, 2026 STAT Plus: Roche ends Huntington’s gene-silencing programs Biotech July 9, 2026 STAT Plus: ARPA-H launches $160 million effort to develop custom gene editing drugs The Readout July 9, 2026 STAT Plus: Prime wins Beam arbitration, clearing path to clinic Subscriber Picks